The University of Texas MD Anderson Cancer Center President, Ronald DePinho, M.D., has received the acclaimed Agilent Thought Leader Award for leading a pioneering translational research program that focuses on pancreatic cancer, one of the most fatal and complicated cancers to treat. The Thought Leader Award was given to only three individuals for the year 2012, and shows recognition to researchers with breakthroughs considered vital to the life sciences.
DePinho’s work on pancreatic cancer metabolimics led him to be nominated for the award, and as a result, will receive instrumentation and support to further the analysis of the metabolic flux observable in the preliminary stages of pancreatic cancer.
DePinho is quoted in EurekAlert:
“I’m honored to receive this award. I’ve had a long-standing focus on pancreatic cancer, as it remains one of the most difficult to treat cancers due to the lack of effective therapeutic strategies. This technology will allow us to rapidly identify new targets that drive its formation, progression and maintenance, which will translate into clinical advances.”
Although it has long been established in oncologic research that one of the distinctive features of cancer cells is their altered metabolism, it is only recently that technology has allowed researchers to pinpoint specific and susceptible alterations. DePinho’s team will collaborate with fellow researchers from MD Anderson’s Institute for Applied Cancer Science (IACS) to fully utilize the granted Agilent technology to conduct further studies on this phenomenon.